Brief: Suven Life Sciences Says Positive Topline Results From A Phase-2 Study Evaluating Samelisant Excessive Daytime Sleepiness

Suven Life Sciences

30/10/2023 09:44

Oct 30 (Reuters) - Suven Life Sciences Ltd  SUVP.NS :
    * POSITIVE TOPLINE RESULTS FROM A PHASE-2 STUDY EVALUATING
SAMELISANT EXCESSIVE DAYTIME SLEEPINESS
    * PLANS TO APPROACH USFDA IN Q1 2024 FOR AN END-OF- PHASE-2
MEETING TO DISCUSS STUDY RESULTS
    * PLANS TO SEEK USFDA'S GUIDANCE FOR PIVOTAL PHASE-3 STUDY

Source text for Eikon:  ID:nBSExfcv0 
Further company coverage:  SUVP.NS 

 ((Reuters.Briefs@thomsonreuters.com;))